Hyperfine's Swoop AI MRI Achieves 100% Sensitivity in Detecting ARIA-E in Lecanemab Patients, Data Shows

Hyperfine’s Swoop® AI-powered portable MRI system demonstrated 100% sensitivity in detecting ARIA-E, a specific type of brain swelling associated with the Alzheimer’s drug lecanemab, according to new data presented at the 2025 Alzheimer’s Association International Conference (AAIC). The findings come from the CARE PMR study, which evaluated the system’s performance in monitoring patients undergoing treatment with lecanemab, a medication designed to target early-stage Alzheimer’s disease. The Swoop® system, developed by Hyperfine, is a compact, mobile MRI device that uses artificial intelligence to enhance image quality and diagnostic accuracy. It is designed to bring MRI technology to locations where traditional systems are not feasible, such as rural areas, emergency rooms, and patient homes. The data presented at AAIC highlights the system’s potential to improve the safety and efficacy of Alzheimer’s treatments by enabling more frequent and accessible monitoring of treatment-related side effects. ARIA-E, or Amyloid-Related Imaging Edema or Leukoencephalopathy, is a known risk associated with lecanemab and other amyloid-targeting therapies. Detecting it early is crucial for managing patient care and preventing complications. The study results suggest that Swoop® can reliably identify ARIA-E cases, offering a new tool for clinicians to monitor patients more effectively. The findings were shared during a session at the conference, underscoring the growing role of AI in medical imaging and the potential for portable technologies to expand access to critical diagnostic tools. Hyperfine has positioned Swoop® as a solution for real-time, on-site imaging that can support both clinical and research applications. The data also reflects the broader trend of integrating AI into healthcare to improve diagnostic precision and patient outcomes. With the increasing use of targeted therapies for neurodegenerative diseases, the ability to quickly and accurately assess treatment effects is becoming more important. Hyperfine’s portable MRI technology represents a shift in how medical imaging is conducted, making it more accessible and adaptable to different clinical settings. The company continues to explore ways to apply AI-driven innovations to other areas of medical imaging and patient care.